Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean alpha tocopherol acetate and hydrogen peroxide and silicon dioxide?
Displaying drugs 451 - 475 of 14671 in total

Liotrix

Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion....
Approved
Matched Description: … and combination hormone replacement therapy generally offers no therapeutic advantage. ... It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in ... It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

D-Methionine

Approved
Experimental
Investigational

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …

Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April …

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved

Hydroxyamphetamine

Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. It is indirect sympathomimetic agent which cause dilation of the eye pupil before diagnostic test. Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry...
Approved
Matched Description: … night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and …

Levmetamfetamine

Levomethamphetamine, the L-enantiomer of methamphetamine is a sympathomimetic vasoconstrictor used in some over-the-counter (OTC) nasal decongestant inhalers in the United States.
Approved

Phenyl salicylate

Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in DB00945 ). Phenyl salicylate may...
Approved
Matched Description: … This compound belongs to the class of organic compounds known as depsides and depsidones. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Miscellaneous Analgesics and Antipyretics …

Elbasvir

Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Description: … for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment. ... achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% ... Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly. …
Matched Categories: … elbasvir and grazoprevir …

Lifitegrast

Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Gestrinone

Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatment of endometriosis. Gestrinone was developed in the early 1970s and was tested clinically as...
Approved
Matched Description: … in Europe and North America. ... Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive ... Without significant advantages over other oral contraceptives and with its high cost, gestrinone was …
Matched Categories: … Antigonadotropins and Similar Agents ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

P-nitrobiphenyl

Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.
Approved
Experimental
Investigational

Oxetacaine

Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH levels. Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal ulcer. Oxetacaine is approved by Health Canada since 1995 for...
Approved
Investigational
Matched Description: … Its actions have shown to relieve dysphagia, relieve pain due to reflux, chronic gastritis, and duodenal …
Matched Categories: … Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use …

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …

Parthenolide

Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational

Methoxyphenamine

Approved

Fluticasone

Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. ... Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, ... These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory …
Matched Categories: … formoterol and fluticasone ... salmeterol and fluticasone …

Ivosidenib

Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … and proliferation. ... IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth ... [A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Pomalidomide

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Approved
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Zopiclone

Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Categories: … Zopiclone and prodrugs ... Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Sleep Initiation and Maintenance Disorders ... Miscellaneous Anxiolytics Sedatives and Hypnotics …

Cyclacillin

A cyclohexylamido analog of penicillanic acid.
Approved

Trofinetide

Trofinetide is a novel synthetic analog of glypromate, also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked...
Approved
Investigational
Matched Description: … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. ... glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and ... L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive, motor, and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Deflazacort

Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Iupac: … trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,14,17-trien-8-yl]-2-oxoethyl acetate …
Matched Description: … This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability ... , severely impacting patient quality of life and survival. ... It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. …
Matched Categories: … Sex Hormones and Insulins …

Rifaximin

Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of...
Approved
Investigational
Matched Iupac: … .0^{5,35}.0^{26,34}.0^{27,32}]heptatriaconta-1,3,5(35),9,19,21,25(36),26(34),28,30,32-undecaen-13-yl acetate …
Matched Description: … It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction ... encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and …
Matched Categories: … Alimentary Tract and Metabolism …

Methyl aminolevulinate

Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 451 - 475 of 14671 in total